Acadian Asset Management’s KalVista Pharmaceuticals KALV Stock Holding History

Acadian Asset Management’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-8,736	Closed	-$78K	–	1743
2023 Q2	$78K	Sell	8,736 -155,935	-95%	-$1.44M	﹤0.01%	1453
2023 Q1	$1.29M	Sell	164,671 -343,816	-68%	-$2.57M	0.01%	816
2022 Q4	$3.44M	Buy	508,487 +503,446	+9,987%	+$2.7M	0.02%	543
2022 Q3	$73K	Buy	+5,041	New	+$70.5K	﹤0.01%	1432
2021 Q3	–	Sell	-6,002	Closed	-$144K	–	1856
2021 Q2	$144K	Buy	+6,002	New	+$157K	﹤0.01%	1537

Other funds holding KALV

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Acadian Asset Management's KALV Position: Q3 2023 in Review

Acadian Asset Management sold out of KalVista Pharmaceuticals (KALV) in Q3 2023, closing a stake of 8,736 shares — an estimated $78K sold.

Acadian Asset Management first reported a position in KALV in Q2 2021 and held it in 5 quarters. The position peaked at $3.44M in Q4 2022. 101 funds tracked by Wall St. Rank hold KALV as of Q3 2023.

Acadian Asset Management reported no remaining KalVista Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Acadian Asset Management sold 8,736 KalVista Pharmaceuticals shares in Q3 2023, an estimated $78K.
Acadian Asset Management first reported a position in KalVista Pharmaceuticals in Q2 2021 and held it in 5 quarters.
Acadian Asset Management's KalVista Pharmaceuticals position peaked at $3.44M in Q4 2022.
101 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2023.

Based on Acadian Asset Management's 13F filing for Q3 2023, filed 13 Nov 2023.